Skip to main content

Table 2 Clinical factors associated with the probability of loss of MR4.5

From: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Variables

No. of pts

No. of events

Univariate Analysis

Multivariate analysis

P

HR

95% CI

P

Age

 < 65 years

87

30

    

 ≥ 65 years

13

5

0.778

   

Sex

 Male

43

18

    

 Female

57

17

0.160

   

First treatment

 Interferon

32

7

    

 TKI

68

28

0.031

0.60

0.25 to 1.44

0.249

Frontline TKI

 Imatinib

43

19

    

 Dasatinib

13

4

0.463

   

 Nilotinib

9

2

0.439

   

 Bosutinib

1

1

0.210

   

 Poantinib

2

2

0.100

   

Last TKI before discontinuation

 Imatinib

47

11

    

 Dasatinib

35

16

0.021

   

 Nilotinib

14

6

0.064

   

 Bosutinib

2

1

0.604

   

 Ponatinib

2

1

0.548

   

Frontline and only TKI

 Imatinib

23

8

    

 Dasatinib

13

4

0.892

   

 Nilotinib

7

2

0.970

   

Line of TKI

 1 line

68

18

    

 > 2 line

32

17

0.007

1.43

0.64 to 3.19

0.377

Response at 3 months

 BCR-ABL/ABL < 10% (IS)

53

18

    

 BCR-ABL/ABL ≥ 10% (IS)

3

2

0.213

   

Transcript type

 b3a2

50

17

    

 b2a2

30

10

0.866

   

 b3a2 + b2a2

17

7

0.511

   

Sokal score

 Low

35

10

    

 Intermediate

21

9

0.261

   

 High

4

0

0.999

   

Reason for discontinuation

 Elective

47

15

    

 Adverse effects

53

20

0.557

   

Duration to achieve MR4.5

 < 17 months

47

15

    

 ≥ 17 months

53

20

0.593

   

Duration of MR4.5

 < 72 months

46

31

    

 ≥ 72 months

54

4

< 0.001

0.11

0.03 to 0.41

0.001

Duration of TKI therapy

 < 87 months

34

22

    

 ≥ 87 months

66

13

< 0.001

0.73

0.29 to 1.82

0.501

  1. CI confidence interval, HR hazard ratio, MR4.5 molecular response of 4.5-log reduction from baseline, P P value, TKI tyrosine kinase inhibitor